NCT02925650: Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease
- State
- Completed
- Phase
- Phase 1 and Phase 2
- People
- 18 taking part
- Started
- 2 Mar 2017
- Primary completion
- 10 Dec 2021
- Arms
- Low Dose, Medium Dose, High Dose
- Results
- Posted on the registry
- Papers
- doi:10.1101/2024.03.20.24304638, doi:10.1186/s13195-024-01490-z
- 6 Oct 2016: Trial registered
- 2 Mar 2017: Trial started
- 31 Dec 2021: Trial completed
- 9 May 2023: Trial results posted